Mo Trikha
President & Chief Operating Officer Kivu BioScience, Inc.
Dr. Mohit (Mo) Trikha is the President and COO of Kivu Bioscience. He brings over 25 years of drug development expertise in oncology. He has been instrumental in advancing more than 40 programs from target identification to clinical trials in oncology. Previously, Mo was a venture partner at Apple Tree Partners, and also led oncology early development at AbbVie, where he oversaw the development of discovery-stage programs to clinical proof of concept, focusing on ADCs, bispecifics, and CAR-T therapies. He has contributed to the development of key drugs such as Kadcyla, Polivy, and vismodegib, and chaired collaborations with leading institutions like TeneoBio, Calibr, and The Scripps Research Institute. Earlier in his career, he held roles at Genentech, Centocor/Johnson & Johnson, and Triphase Accelerator.
Seminars
- Understanding why the dose of ADC matters
- Explaining how durability of response may be a better predictor of activity than ORR in early ADC trials
- How can we use predictive biomarkers to improve ADC patient selection; should we be looking beyond biomarkers of response to biomarkers of toxicity?
